Skip to main content

Table 3 Association of risk factors with VTE occurrence

From: Incidence and risk of venous thromboembolism according to primary treatment type in women with endometrial cancer: a population-based study

  The total follow-up period The first six months
VTE DVE PE VTE DVE PE
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Unadjusted HR
 Age per 5 years 1.244 (1.187–1.303) < 0.001 1.205 (1.128–1.287) < 0.001 1.294 (1.216–1.378) < 0.001 1.175 (1.096–1.258) < 0.001 1.151 (1.038–1.275) 0.008 1.177 (1.076–1.287) < 0.001
 Low SES a 1.547 (1.005–2.381) 0.048 1.413 (0.747–2.675) 0.288 1.756 (1.02–3.023) 0.042 0.889 (0.393–2.011) 0.778 0.325 (0.045–2.338) 0.264 1.27 (0.515–3.127) 0.604
 CCI 1.159 (1.112–1.208) < 0.001 1.148 (1.081–1.22) < 0.001 1.164 (1.102–1.229) < 0.001 1.073 (0.999–1.153) 0.054 1.051 (0.938–1.176) 0.392 1.078 (0.983–1.182) 0.603
 Year of endometrial cancer diagnosis 1.116 (1.069–1.165) < 0.001 1.118 (1.051–1.19) < 0.001 1.109 (1.048–1.174) < 0.001 1.138 (1.071–1.209) < 0.001 1.145 (1.045–1.254) 0.004 1.129 (1.045–1.221) 0.002
 Types of primary treatment b,c
  Surgery d 0.91 (0.696–1.189) 0.489 0.995 (0.677–1.463) 0.979 0.857 (0.603–1.219) 0.391 1.03 (0.691–1.535) 0.885 1.137 (0.618–2.093) 0.68 1.034 (0.613–1.747) 0.899
  Radiotherapy 0.79 (0.343–1.818) 0.579 1.11 (0.393–3.134) 0.843 0.676 (0.209–2.182) 0.512 1.26 (0.446–3.576) 0.661 2.259 (0.644–7.927) 0.203 1.087 (0.252–4.684) 0.911
  Chemotherapy 2.614 (1.554–4.395) < 0.001 2.234 (0.986–5.063) 0.054 2.934 (1.538–5.596) 0.001 2.956 (1.518–5.757) 0.001 1.756 (0.5–6.163) 0.379 3.827 (1.719–8.521) 0.001
  Hormone therapy 1.261 (0.83–1.915) 0.278 1.173 (0.628–2.192) 0.617 1.207 (0.693–2.101) 0.506 0 (0-Infinite) 0.991 0 (0-Infinite) 0.994 0 (0-Infinite) 0.991
Adjusted HR e
 Age per 5 years 1.231 (1.175–1.29) < 0.001 1.191 (1.114–1.273) < 0.001 1.279 (1.201–1.363) < 0.001 1.147 (1.066–1.235) < 0.001 1.125 (1.006–1.257) 0.038 1.148 (1.043–1.263) 0.005
 Low SES a 1.119 (0.723–1.734) 0.614 1.075 (0.564–2.052) 0.826 1.205 (0.694–2.094) 0.507 0.722 (0.317–1.646) 0.439 0.271 (0.037–1.966) 0.197 1.035 (0.416–2.578) 0.941
 CCI 1.121 (1.071–1.173) < 0.001 1.125 (1.054–1.2) < 0.001 1.112 (1.047–1.181) < 0.001 1.057 (0.979–1.142) 0.156 1.056 (0.936–1.191) 0.374 1.052 (0.953–1.162) 0.316
 Year of endometrial cancer diagnosis 1.112 (1.064–1.162) < 0.001 1.116 (1.048–1.189) 0.001 1.101 (1.039–1.167) 0.001 1.124 (1.057–1.194) < 0.001 1.141 (1.041–1.25) 0.005 1.11 (1.026–1.201) 0.009
 Types of primary treatment b,c
  Surgery d 1.081 (0.821–1.424) 0.579 1.166 (0.784–1.732) 0.448 1.033 (0.718–1.486) 0.862 1.111 (0.739–1.671) 0.614 1.202 (0.645–2.239) 0.563 1.122 (0.657–1.917) 0.672
  Radiotherapy 0.849 (0.368–1.957) 0.701 1.196 (0.423–3.382) 0.736 0.72 (0.223–2.33) 0.584 1.383 (0.487–3.927) 0.542 2.516 (0.714–8.866) 0.151 1.174 (0.272–5.076) 0.83
  Chemotherapy 2.334 (1.38–3.949) 0.002 1.944 (0.852–4.437) 0.114 2.742 (1.424–5.278) 0.003 2.532 (1.291–4.966) 0.007 1.452 (0.411–5.137) 0.563 3.366 (1.496–7.576) 0.003
  Hormone therapy 2.073 (1.356–3.17) 0.001 1.837 (0.973–3.469) 0.061 2.086 (1.19–3.657) 0.01 0 (0-Infinite) 0.991 0 (0-Infinite) 0.994 0 (0-Infinite) 0.994
  1. CCI Charlson comorbidity index; CI confidence interval; DVT deep vein thrombosis; HIRA health insurance review & assessment service; HR hazard ratio; SES socioeconomic status; PE pulmonary embolism; VTE venous thromboembolism
  2. a The reference was mid- or high- SES
  3. b Primary treatments refers to the first cancer treatments
  4. c) The reference was no treatment. In patients that received no treatment, the incidence of VTE after diagnosis of endometrial cancer was evaluated
  5. d Neoadjuvant chemotherapy followed by laparotomy or laparoscopy was considered as surgery
  6. e The data were adjusted for all risk factors (age per 5 years, SES, CCI, year of endometrial cancer diagnosis, and types of primary treatment)